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Abstract—The reference standard methyl (2-amino-5-(benzylthio)thiazolo[4,5-d]pyrimidin-7-yl)-D-leucinate (5) and its precursor 2-
amino-5-(benzylthio)thiazolo[4,5-d]pyrimidin-7-yl)-D-leucine (6) were synthesized from 6-amino-2-mercaptopyrimidin-4-ol and BnBr 
with overall chemical yield 7% in five steps and 4% in six steps, respectively. The target tracer [11C]methyl (2-amino-5-
(benzylthio)thiazolo[4,5-d]pyrimidin-7-yl)-D-leucinate ([11C]5) was prepared from the acid precursor with [11C]CH3OTf through O-
[11C]methylation and isolated by HPLC combined with SPE in 40-50% radiochemical yield, based on [11C]CO2 and decay corrected to 
end of bombardment (EOB). The radiochemical purity was >99%, and the specific activity (SA) at EOB was 370-1110 GBq/µmol with a 
total synthesis time of ~40-minutes from EOB. The radioligand depletion experiment of [11C]5 did not display specific binding to 
CX3CR1, and the competitive binding assay of ligand 5 found much lower CX3CR1 binding affinity.  
Keywords: [11C]Methyl (2-amino-5-(benzylthio)thiazolo[4,5-d]pyrimidin-7-yl)-D-leucinate; Fractalkine receptor (CX3CR1); 
Radiosynthesis; Radioligand depletion experiment; Competitive binding assay; Positron emission tomography (PET). 
CX3C chemokine receptor 1 (CX3CR1), also known as 
fractalkine receptor or G-protein coupled receptor 13 
(GPR13), is a protein in humans.1 CX3CR1 binds the 
chemokine CX3CL1, also called fractalkine ligand or 
neurotactin.2 CX3CR1 is expressed in the brain, spleen, 
and in subpopulations of leukocytes, cells of monocytic 
lineage, and neutrophils but also in lymphocytes, and 
associated with various cancer, cardiovascular and 
neurological diseases such as Alzheimer’s disease (AD) 
and Parkinson’s disease (PD).3 CX3CR1 is an 
interesting therapeutic target, and many selective 
CX3CR1 antagonists have been developed.4,5 Methyl (2-
amino-5-(benzylthio)thiazolo[4,5-d]pyrimidin-7-yl)-D-
leucinate (5) recently developed by AstraZeneca is a 
potent and selective CX3CR1 antagonist with Ki 8.3 and 
1940 nM for CX3CR1 and CXCR2, respectively, and 
selectivity index (SI) 230.6 CX3CR1 has also become a 
promising target for molecular imaging of CX3CR1-
mediated diseases and image-guided therapy using 
positron emission tomography (PET) modality. 
However, radionuclides including carbon-11 and 
fluorine-18 labeled CX3CR1 antagonists are still not 
reported. In our previous work, we have developed 
carbon-11-labeled naphthalene-sulfonamides as 
potential radioligands for PET imaging of chemokine 
receptor 8 (CCR8), as indicated in Figure 1.7 In this 
ongoing study, we first target CX3CR1 and develop 
radiolabeled CX3CR1 antagonists. Here we report the 
synthesis and preliminary biological evaluation of 
[11C]methyl (2-amino-5-(benzylthio)thiazolo[4,5-
d]pyrimidin-7-yl)-D-leucinate ([11C]5) as a new 
candidate PET agent for imaging of CX3CR1. 
The reference standard 5 and its desmethylated acid 
precursor 2-amino-5-(benzylthio)thiazolo[4,5-
d]pyrimidin-7-yl)-D-leucine (6) were synthesized as 
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depicted in Scheme 1, according to the literature method 
with modifications.6,8 The alkylation of commercially 
available starting material 2-amino-6-hydroxy-2-
mercaptopyrimidine with benzyl bromide in 1 M NaOH 
gave compound 1 in 92% yield, which was collected by 
filtration and was sufficiently pure to be used in next 
step without further purification. Compound 1 was 
reacted with potassium thiocyanate, pyridine, and 
bromine in N,N-dimethylformamide (DMF) to provide 
intermediate 2 in 83% yield, which was followed by 
condensation at elevated temperature to afford the 
thiazole 3 in 95% yield. The 7-hydroxy group of 
compound 3 was then converted to the corresponding 
chloride 4 to introduce a better leaving group chloro via 
a Vilsmeier reaction in 91% yield. In this reaction, the 
organic base N,N-dimethylanline was removed, 
consequently the reaction process and workup 
procedure were simplified, and the yield was increased 
from 60% to 91%.6 The chloro group of compound 4 
was subsequently displaced in a nucleophilic aromatic 
substitution reaction with excess methyl D-leucinate in 
the solvent anhydrous CH3CN or N-methylpyrrolidone 
and N,N-diisopropylethylamine (DIPEA) as a catalyst to 
give the standard compound 5 in only 11% yield. The 
poor yield is due to that it is difficult to displace 
aromatic chloro with methyl D-leucinate. The 
hydrolysis of compound 5 in KOH/methanol at room 
temperature (RT) for 21 h provided the acid precursor 6 
in 50% yield. 
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Figure 1. PET radioligands for imaging of CCR8.  
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Scheme 1. Synthesis of methyl (2-amino-5-(benzylthio)thiazolo[4,5-
d]pyrimidin-7-yl)-D-leucinate (5) and 2-amino-5-
(benzylthio)thiazolo[4,5-d]pyrimidin-7-yl)-D-leucine (6). 
 
Synthesis of the target tracer ([11C]5) is shown in 
Scheme 2. The acid precursor 6 underwent O-
[11C]methylation9-11 using the reactive [11C]methylating 
agent [11C]methyl triflate ([11C]CH3OTf)12,13 in 
acetonitrile at 80 °C under basic condition (2 N NaOH). 
The product was isolated by semi-preparative reverse-
phase (RP) high performance liquid chromatography 
(HPLC) with a C-18 column, and then concentrated by 
solid-phase extraction (SPE)14,15 with a disposable C-18 
Light Sep-Pak cartridge to produce the corresponding 
pure radiolabeled compound [11C]5 in 40-50%  
radiochemical yield, decay corrected to end of 
bombardment (EOB), based on [11C]CO2. 
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Scheme 2. Synthesis of [11C]methyl (2-amino-5-(benzylthio)thiazolo[4,5-
d]pyrimidin-7-yl)-D-leucinate ([11C]5). 
 
The radiosynthesis process included three stages: 1) 
labeling reaction; 2) purification; and 3) formulation. 
The radiolabeled precursor we used is more reactive 
[11C]CH3OTf, instead of commonly used [11C]methyl 
iodide ([11C]CH3I),16 in O-[11C]methylation to improve 
radiochemical yield of [11C]5. An Eckert & Ziegler 
Modular Lab C-11 Methyl Iodide/Triflate module is 
employed to produce [11C]methylating agent either 
[11C]CH3OTf or [11C]CH3I ([11C]CH3Br passed through 
a NaI column). The direct comparison between 
[11C]CH3OTf and [11C]CH3I confirmed the 
aforementioned result. The labeling reaction was 
conducted using a V-vial method. Addition of aqueous 
NaHCO3 to quench the radiolabeling reaction and to 
dilute the radiolabeling mixture prior to the injection 
onto the semi-preparative HPLC column for purification 
gave better separation of [11C]5 from its acid precursor 
6. We used Sep-Pak trap/release method instead of 
rotatory evaporation for formulation to improve the 
chemical purity of radiolabeled product [11C]5. In 
addition, a C18 Light Sep-Pak to replace a C18 Plus 
Sep-Pak allowed final product formulation with ≤5% 
ethanol.17 Overall, it took ~40 min for synthesis, 
purification and dose formulation.     
 
The radiosynthesis was performed in a self-designed 
automated multi-purpose [11C]-radiosynthesis 
module.18-20 This radiosynthesis module facilitated the 
overall design of the reaction, purification and 
reformulation capabilities in a fashion suitable for 
adaptation to preparation of human doses. In addition, 
the module is designed to allow in-process measurement 
of [11C]-tracer specific activity (SA, GBq/µmol at EOB) 
using a radiation detector at the outlet of the HPLC-
portion of the system. For the reported syntheses, the 
product SA was in a range of 370-1110 GBq/µmol at 
EOB. The major factors including [11C]-target and 
[11C]-radiosynthesis unit that affect the EOB SA 
significantly to lead to such a wide range from 370 to 
 
1110 GBq/µmol have been discussed in our previous 
works.21 The general methods to increase SA have been 
described as well, and the SA of our [11C]-tracers is 
significantly improved.21 The ‘wide range’ of SA we 
reported is for the same [11C]-tracer produced in 
different days, because very different [11C]-target and 
[11C]-radiosynthesis unit situations would make SA in a 
wide range. Likewise, the methods to minimize such 
wide range of SA from practice perspective have been 
provided in our previous works.21 At the end of 
synthesis (EOS), the SA of [11C]-tracer was determined 
again by analytical HPLC,22 calculated, decay corrected 
to EOB, and based on [11C]CO2, which was in 
agreement with the ‘on line’ determined value. In each 
our [11C]-tracer production, if semi-preparative HPLC 
was used for purification, then the SA of [11C]-tracer 
was assessed by both semi-preparative HPLC (during 
synthesis) and analytical HPLC (EOS); if SPE was used 
for purification, then the SA of [11C]-tracer was only 
measured by analytical HPLC at EOS.11                
 
Chemical purity and radiochemical purity were 
determined by analytical HPLC.22 The chemical purity 
of the precursor and reference standard was >90%. The 
radiochemical purity of the target tracer was >99% 
determined by radio-HPLC through γ-ray (PIN diode) 
flow detector, and the chemical purity of the target 
tracer was >90% determined by reversed-phase HPLC 
through UV flow detector.   
 
-1 4 -1 2 -1 0 -8 -6 -4
0
5 0
1 0 0
1 5 0
C X 3 C R 1  B in d in g
C o n c  [ lo g M ]
%
 S
p
e
c
if
ic
  
B
in
d
in
g
B u ffe r
F ra c ta lk in e
L ig a n d
     
Figure 2. The result of the competitive binding assay of ligand 5. 
 
The preliminary biological evaluation of the radioligand 
[11C]5 was performed by a radioligand depletion 
experiment.23 In this experiment, a wide range of 
protein was used for the optimization of the assay 
conditions. For the law of mass action to be valid, the 
protein and radioligand concentration need to be at 
levels where no more than 10% of the total radioligand 
added is bound to the protein. Otherwise the radioligand 
is considered depleted and specialized formulas for 
radioligand depletion must be used for analysis of the 
data in saturation or competitive binding assays. An 
optimized binding assay uses protein levels where the 
radioligand is depleted no more than 10%, and where 
sufficient signal to background binding levels, at least 5 
fold total binding/non-specific binding ratio, are 
obtained. To achieve both of these ends, a wide range of 
membrane protein concentrations was tested to get the 
optimal level for the assay. The result indicated no 
specific binding of [11C]5 to CX3CR1. The method was 
further optimized by improving the solubility of the 
tracer [11C]5, and the result remained same. We are 
puzzled by this disappointing result. Then the 
competitive binding assay of ligand 5 was conducted 
following the literature method.6 The assays were 
incubated at 25 °C for 2 h, and the results are shown in 
Figure 2. [125I]Fractalkine was used as the radioligand, 
and fractalkine and buffer were used as a positive 
control and a negative control, respectively. Likewise, 
there was not specific binding of 5 to CX3CR1, since its 
binding curve is similar to that of the negative control 
buffer. We were unable to reproduce the reported 
result.6 However, the result of the competitive binding 
assay of ligand 5 was consistent with the result of 
radioligand [11C]5 depletion experiment. Thus, we can 
conclude compound 5 is not a potent and selective 
antagonist of CX3CR1. 
 
The experimental details and characterization data for 
compounds 1-6 and for the tracer [11C]5, as well as 
radioligand [11C]5 depletion experiments and ligand 5 
binding assays are given.24  
 
In summary, synthetic routes with reasonable to high 
yields have been developed to produce the reference 
standard 5, acid precursor 6 and target radioligand 
[11C]5. The radiosynthesis employed [11C]CH3OTf for 
O-[11C]methylation at the carboxylic acid position of 
the desmethyled precursor, followed by product 
purification and isolation using a semi-preparative RP 
HPLC combined with SPE. [11C]5 was obtained in high 
radiochemical yield, radiochemical purity and chemical 
purity, with a reasonably short overall synthesis time, 
and high specific activity. The preliminary biological 
evaluation via radioligand [11C]5 depletion experiment 
and ligand 5 competitive binding assay suggested the 
compound 5 is not a potent and selective CX3CR1 
ligand, consequently, the tracer [11C]5 is not able to be a 
CX3CR1 radioligand.   
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3H, CH3), 4.33 (dd, J = 5.5, 13.5 Hz, 1H, SCHH), 
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5.96 (s, 1H, NH), 7.18 (t, J = 7.0 Hz, 1H, Ph-H), 7.23 
(d, J = 7.5 Hz, 2H, Ph-H), 7.38 (d, J = 7.5 Hz, 2H, Ph-
H). MS (ESI): 417 ([M+H]+, 100%); MS (ESI): 416 
([M-H]-, 15%). 
(g). 2-Amino-5-(benzylthio)thiazolo[4,5-d]pyrimidin-
7-yl)-D-leucine (6): To a solution of compound 5 (83 
mg, 0.2 mmol) in methanol (40 mL) was added KOH 
(0.5 g, 8.9 mmol). The reaction mixture was stirred at 
RT for 21 h. Then the reaction mixture was 
concentrated in vacuo, and the mixture was 
neutralized with 1 N HCl. The mixture was extracted 
with EtOAc (3 × 60 mL), and the combined organic 
layers were washed with brine, dried over MgSO4, and 
concentrated. The resulting residue was purified by 
column chromatography on silica gel with eluent (5:95 
to 30:70 MeOH/CH2Cl2) to give 6 as a white off solid 
(40 mg, 50%). Rf = 0.24 (1:5 MeOH/CH2Cl2), mp 245 
°C (decomposed). 1H NMR (MeOD-d4): δ 0.92 (d, J = 
6.5 Hz, 3H, CH3), 0.94 (d, J = 6.5 Hz, 3H, CH3), 1.71-
1.76 (m, 2H, CH2), 1.77-1.79 (m, 1H, CH), 4.32 (d, J 
= 13.5 Hz, 1H, SCHH), 4.47 (d, J = 13.5 Hz, 1H, 
SCHH), 4.75-4.77 (m, 1H, NCH), 7.18 (t, J = 7.5 Hz, 
1H, Ph-H), 7.26 (t, J = 7.0 Hz, 2H, Ph-H), 7.40 (d, J = 
7.5 Hz, 2H, Ph-H). 13C NMR (MeOD-d4): δ 22.33, 
23.70, 26.28, 36.10, 43.03, 55.86, 127.87, 129.38, 
130.00, 139.85, 155.98, 157.13, 168.53, 169.67, 
173.64, 180.60. MS (ESI): 404 ([M+H]+, 100%); MS 
(ESI): 402 ([M-H]-, 10%). HRMS (ESI) calcd for 
C18H21N5O2S2H, 404.1215 ([M+H]+); found 404.1223.  
(h). ([11C]methyl (2-amino-5-(benzylthio)thiazolo[4,5-
d]pyrimidin-7-yl)-D-leucinate ([11C]5): [11C]CO2 was 
produced by the 14N(p,α)11C nuclear reaction in the 
small volume (9.5 cm3) aluminum gas target provided 
with the Siemens RDS-111 Eclipse cyclotron. The 
target gas consisted of 1% oxygen in nitrogen 
purchased as a specialty gas from Praxair, 
Indianapolis, IN. Typical irradiations used for the 
development were 58 µA beam current and 15 min on 
target. The production run produced approximately 
25.9 GBq of [11C]CO2 at EOB. The acid precursor (6, 
0.1-0.3 mg) was dissolved in CH3CN (300 µL). To 
this solution was added aqueous NaOH (2 N, 2 µL). 
The mixture was transferred to a small reaction vial. 
No-carrier-added (high specific activity) [11C]CH3OTf 
that was produced by the gas-phase production 
 
method13 within 12 min from [11C]CO2 through 
[11C]CH4 and [11C]CH3Br with silver triflate (AgOTf) 
column was passed into the reaction vial at RT until 
radioactivity reached a maximum (2 min), and then 
the reaction vial was isolated and heated at 80 °C for 3 
min. The contents of the reaction vial were diluted 
with aqueous NaHCO3 (0.1 M, 1 mL). The reaction 
vial was connected to a 3-mL HPLC injection loop. 
The labeled product mixture solution was injected 
onto the semi-preparative HPLC column for 
purification. The product fraction was collected in a 
recovery vial containing 30 mL water. The diluted 
tracer solution was then passed through a C-18 Sep-
Pak Light cartridge, and washed with water (3 × 10 
mL). The cartridge was eluted with EtOH (3 × 0.4 
mL) to release the labeled product, followed by saline 
(10-11 mL). The eluted product was then sterile-
filtered through a Millex-FG 0.2 µm membrane into a 
sterile vial. Total radioactivity was assayed and total 
volume (10-11 mL) was noted for tracer dose 
dispensing. The overall synthesis time including 
HPLC-SPE purification and reformulation was ~40 
min from EOB. The decay corrected radiochemical 
yield was 40-50%. Retention times in the analytical 
HPLC system were: tR 6 = 3.08 min, tR 5 = 5.64 min, 
tR [11C]5 = 5.73 min. Retention times in the 
preparative HPLC system were: tR 6 = 3.75 min, tR 5 = 
8.36 min, tR [11C]5 = 8.48 min. 
(i). Radioligand depletion experiments: Radioligand 
depletion experiments were performed using CX3CR1 
cell membrane preps (Millipore) to measure the bound 
radioligand [11C]5 concentration. Four replicates of 
membranes (0.004-4.5 mg protein/mL assay medium) 
were incubated with 1 nM or 10 nM [11C]5 in a final 
volume of 0.2 mL in assay buffer (25 mM HEPES, 10  
mM MgCl2, 1 mM CaCl2,1 mM EDTA, pH 7.4) for 30 
min at 25 °C. Unlabeled compound 5 was added at 
100 fold excess of [11C]5 to determine non-specific 
binding. In some experiments 10% Solutol (Sigma) 
was added to increase the solubility of the radioligand. 
To measure the total radioactivity added to the 
experiment, 20 µL of stock radioligand [11C]5 
(amount added to each experimental well) was spotted 
onto a unifilter GF/B plate then allowed to air dry. An 
additional aliquot was added to a scintillation vial and 
counted on a Beckman LSC to determine CPMs 
(counts per minute) added. For termination of the 
binding reaction, the samples were filtered onto GF/B 
unifilter plates (Perkin Elmer) that had been pre-
soaked in 20 mM tetrasodium pyrophosphate for 30 
min using a unifilter-96 cell harvester (Perkin-Elmer). 
Plates were washed 6 times with ice cold saline, dried 
under a vacuum, and exposed to a TR2025 
phosphorscreen (GE Healthcare) for 20 to 60 min. 
Exposed phophorscreens were then read on a Typhoon 
FLA-7000IP (GE Healthcare) along with [11C]5 
calibration standards. CPMs were determined by 
calibrating the image to the CPMs in the calibration 
standards via MCID analysis Software.  
(j). Ligand competitive binding assays: To compare 
the affinity of the unlabeled compound 5 (ligand) with 
the native ligand, fracktalkine, competitive binding 
assays were performed using the above cell 
membrane. Approximately 0.5 µg per well of 
membrane protein was incubated with 11 different 
concentrations of the compound over a six log unit 
range. Assays were run with 0.025 nM 
[125I]fractalkine (Perkin Elmer) in assay buffer as 
above with the addition of 0.5% BSA (bovine serum 
albumin) to reduce non-specific binding. Triplicate 
determinations were done at each concentration of the 
test compound. Unlabeled fractalkine (Peprotech) was 
used to determine non-specific binding. Each assay 
plate included a positive control (fractalkine) and a 
negative control (buffer). Assays were incubated at 25 
°C for 2 h. After equilibrium was reached, bound 
radioligand was separated from free radioligand using 
a Perkin Elmer 96-well filtration apparatus. Plates 
were washed at least 3 times with ice cold saline. 
Filters were quickly dried under a vacuum and 
radioactive counts collected on a Perkin Elmer 
TopCount microplate scintillation counter using a 
counting protocol for 125I. Data was analyzed with 
Prism 7 (GraphPad Software Inc.) to calculate Ki 
values.  
